低剂量沙利度胺联合DP方案治疗雄激素非依赖型前列腺癌

Low Dose Thalidomide Combined with DP Regimen in the Treatment of Androgen-independent Prostate Cancer

目的观察低剂量沙利度胺联合DP方案治疗雄激素非依赖型前列腺癌的临床疗效及毒副反应。方法 36例雄激素非依赖型前列腺癌患者随机分为2组,每组18例。治疗组给予低剂量沙利度胺联合DP方案,对照组仅给予DP方案治疗。治疗后评价疗效及毒副反应。结果治疗组与对照组中位生存期分别为20.3个月、17.5个月(P<0.05)。结论低剂量沙利度胺联合DP方案治疗雄激素非依赖型前列腺癌能延长患者生存期。

Objective To observe the efficacy and toxicities of low dose thalidomide combined with DP regimen in the treatment of androgen-independent prostate cancer. Methods Thirty-six patients with androgen-independent prostate cancer were randomly divided into the treatment group （ 18 patients） and the control group （ 18 patients）. The 18 patients in the treatment group received the low dose thalidomide plus DP regimen; the 18 patients in the control group received the DP regimen. The efficacy and toxicities were evaluated after the treatment. Results The median survival time of the treatment group was 20.3 months, and was 17.5 months of the control group （P 〈 0.05）. Conclusion The low dose thalidomide combined with DP regimen can prolong survival time for androgen-independent prostate cancer.